| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3303584 | Gastrointestinal Endoscopy | 2013 | 8 Pages |
BackgroundSubjective and especially objective data after endoluminal full-thickness gastroplication are scarce.ObjectiveTo evaluate symptoms and reflux activity 12 months after gastroplication by using multichannel intraluminal impedance monitoring.DesignOpen-label, prospective, single-center study.SettingTertiary referral hospital in Zell am See, Austria.PatientsSubjects without hiatal hernias with documented GERD and persistent or recurrent symptoms despite treatment with a proton pump inhibitor.InterventionsA total of 36 patients underwent endoscopic full-thickness gastroplication with 1 or more Plicator implants.Main Outcome MeasurementsMean Gastrointestinal Quality of Life Index and reflux-specific symptom scores significantly improved on follow-up (P < .01). Atypical reflux, gas/bloating, and bowel dysfunction–specific symptom scores as well as belching and dysphagia scores improved. Twenty-two patients returned for esophageal manometry and multichannel intraluminal impedance testing 1 year after surgery. DeMeester scores decreased from 20 to 10 (P < .029). The median numbers of total, acid, proximal, upright, and recumbent reflux episodes were all significantly reduced (P < .05). Manometric data were virtually unchanged. The percentage of patients taking proton pump inhibitors on daily basis after the procedure was 11.5%. There was only 1 postprocedure incident (bleeding) that required intervention. Three of 36 patients (8.3%) were considered treatment failures because of persistent symptoms and were assigned to undergo laparoscopic fundoplication.LimitationsNo randomized comparison with a sham procedure or laparoscopic fundoplication; follow-up interval.ConclusionsEndoscopic plication is safe and improves objective and subjective parameters at 1-year follow-up, without side effects seen after laparoscopic fundoplication. Further studies on the clinical merit of this procedure in specific patient populations are warranted. (Clinical Trial registration number: NCT01453985.)
